No Data
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
H.C. Wainwright Upgrades Prelude Therapeutics(PRLD.US) to Buy Rating, Maintains Target Price $5
H.C. Wainwright analyst Robert Burns upgrades $Prelude Therapeutics(PRLD.US)$ to a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 28.2%
KIVA SALES LEADER JOINS PRELUDE TO ACCELERATE EXPANSION ACROSS THE CANNABIS SUPPLY CHAIN
Prelude Therapeutics Price Target Maintained With a $7.00/Share by JMP Securities
Prelude Therapeutics (PRLD) Gets a Sell From Barclays
JMP Securities Maintains Prelude Therapeutics(PRLD.US) With Buy Rating, Maintains Target Price $7
JMP Securities analyst Reni Benjamin maintains $Prelude Therapeutics(PRLD.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 33.